Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -68.73% is 62% below its 5-year average of -42.50%, near the high end of its 5-year range (-323.27%–35.58%).
As of the fiscal period ended Tuesday, June 30, 2026. 209.81% below its 12-month average of -22.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -68.73%.
RETURN ON EQUITY (ROE)
-68.73%
RETURN ON EQUITY (ROE) AVG TTM
-22.18%
RETURN ON EQUITY (ROE) AVG 3Y
-63.87%
RETURN ON EQUITY (ROE) AVG 5Y
-42.50%
RETURN ON EQUITY (ROE) AVG 10Y
-32.89%
RETURN ON EQUITY (ROE) AVG 15Y
-42.82%
RETURN ON EQUITY (ROE) AVG 20Y
-65.59%
CURRENT VS TTM AVG
-209.81%
CURRENT VS 3Y AVG
-7.60%
CURRENT VS 5Y AVG
-61.72%
CURRENT VS 10Y AVG
-108.95%
CURRENT VS 15Y AVG
-60.49%
CURRENT VS 20Y AVG
-4.78%
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 491 covered companies
CURRENT VS SECTOR MEDIAN
-78.28%
vs the sector median at left
Arrowhead Pharmaceuticals, Inc.
Market Cap
$8.64B
Return on Equity (ROE)
-68.73%
TTM Avg
-22.18%
3Y Avg
-63.87%
5Y Avg
-42.50%
Market Cap
$8.70B
Return on Equity (ROE)
-19.85%
TTM Avg
-23.25%
3Y Avg
-28.82%
5Y Avg
-25.53%
Market Cap
$8.77B
Return on Equity (ROE)
17.77%
TTM Avg
-40.95%
3Y Avg
-11.78%
5Y Avg
-8.64%
Market Cap
$8.90B
Return on Equity (ROE)
-230.05%
TTM Avg
-355.61%
3Y Avg
-251.82%
5Y Avg
-322.00%
Market Cap
$8.36B
Return on Equity (ROE)
26.84%
TTM Avg
-21.41%
3Y Avg
-36.14%
5Y Avg
-25.75%
Market Cap
$9.35B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$9.35B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$9.56B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
Market Cap
$9.62B
Return on Equity (ROE)
17.77%
TTM Avg
13.11%
3Y Avg
0.20%
5Y Avg
-3.65%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | $8.64B | -68.73% | -22.18% | -63.87% | -42.50% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.70B | -19.85% | -23.25% | -28.82% | -25.53% |
| Caris Life Sciences, Inc. (CAI)vs › | $8.77B | 17.77% | -40.95% | -11.78% | -8.64% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.90B | -230.05% | -355.61% | -251.82% | -322.00% |
| Oscar Health, Inc. (OSCR)vs › | $8.36B | 26.84% | -21.41% | -36.14% | -25.75% |
| Insulet Corp. (PODD)vs › | $9.35B | 26.39% | 25.41% | 19.99% | 14.02% |
| Bruker Corporation (BRKRP)vs › | $9.35B | -2.97% | 3.00% | 15.91% | 17.66% |
| Bruker Corporation (BRKR)vs › | $9.56B | -2.97% | 3.00% | 15.91% | 17.66% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.62B | 17.77% | 13.11% | 0.20% | -3.65% |
| Cytokinetics, Incorporated (CYTK)vs › | $7.66B | N/A | 277.25% | 262.80% | 141.77% |
ROE
-68.7%
ROA
-15.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -68.73% |
| 2026-03-31 | -49.01% |
| 2025-12-31 | 35.58% |
| 2025-09-30 | -0.35% |
| 2025-06-30 | -28.42% |
| 2025-03-31 | -21.07% |
| 2024-09-30 | -323.27% |
| 2024-06-30 | -162.95% |
| 2024-03-31 | -97.31% |
| 2023-12-31 | -185.04% |
| 2023-09-30 | -75.65% |
| 2023-06-30 | -49.64% |
| 2023-03-31 | -33.62% |
| 2022-12-31 | -40.98% |
| 2022-09-30 | -44.18% |
| 2022-06-30 | -33.91% |
| 2022-03-31 | -24.72% |
| 2021-12-31 | -49.12% |
| 2021-09-30 | -34.45% |
| 2021-06-30 | -28.82% |
| 2021-03-31 | -24.60% |
| 2020-12-31 | -22.58% |
| 2020-09-30 | -18.31% |
| 2020-06-30 | -4.95% |
| 2020-03-31 | 1.93% |
| 2019-12-31 | 10.65% |
| 2019-09-30 | 27.79% |
| 2019-06-30 | 20.12% |
| 2019-03-31 | 4.76% |
| 2018-12-31 | -16.98% |
| 2018-09-30 | -56.84% |
| 2018-06-30 | -53.19% |
| 2018-03-31 | -38.80% |
| 2017-12-31 | -50.16% |
| 2017-09-30 | -42.22% |
| 2017-06-30 | -50.91% |
| 2017-03-31 | -63.66% |
| 2016-12-31 | -76.25% |
| 2016-09-30 | -85.50% |
| 2016-06-30 | -140.45% |
| 2016-03-31 | -108.43% |
| 2015-12-31 | -95.38% |
| 2015-09-30 | -83.45% |
| 2015-06-30 | -68.26% |
| 2015-03-31 | -58.94% |
| 2014-12-31 | -48.25% |
| 2014-09-30 | -35.20% |
| 2014-06-30 | -26.77% |
| 2014-03-31 | -23.17% |
| 2013-12-31 | -44.91% |
| 2013-09-30 | -113.25% |
| 2013-06-30 | -65.12% |
| 2013-03-31 | -464.48% |
| 2012-12-31 | -259.11% |
| 2012-09-30 | -210.99% |
| 2012-06-30 | -198.49% |
| 2012-03-31 | -101.48% |
| 2011-12-31 | -25.83% |
| 2011-09-30 | -24.46% |
| 2011-06-30 | -22.18% |
| 2011-03-31 | -7.51% |
| 2010-12-31 | -70.40% |
| 2010-09-30 | -63.83% |
| 2010-06-30 | -71.49% |
| 2010-03-31 | -159.71% |
| 2009-12-31 | -192.21% |
| 2009-09-30 | -397.46% |
| 2009-06-30 | -659.84% |
| 2008-12-31 | -597.71% |
| 2008-09-30 | -220.19% |
| 2008-06-30 | -198.50% |
| 2008-03-31 | -162.50% |
| 2007-12-31 | -132.34% |
| 2007-09-30 | -113.79% |
| 2007-06-30 | -93.86% |
| 2007-03-31 | -93.03% |
| 2006-12-31 | -72.25% |
| 2006-09-30 | -69.19% |
| 2006-06-30 | -40.23% |
| 2006-03-31 | -33.96% |
| 2005-12-31 | -35.07% |
| 2005-09-30 | -25.29% |
| 2005-06-30 | -18.94% |
| 2005-03-31 | -24.61% |
| 2004-12-31 | -46.86% |
| 2004-09-30 | -26.43% |
| 2004-06-30 | -8.41% |
| 2004-03-31 | -2.85% |
| 2003-12-31 | -12.15% |
| 2003-09-30 | -6.71% |
